PGlycoprotein and Alzheimer's Disease

Jashvant Unadkat, PhD
University of Washington (Seattle, WA)
Year Awarded:
2007
Grant Duration:
April 1, 2007 to March 31, 2008
Disease:
Alzheimer's Disease
Award Amount:
$134,896
Grant Reference ID:
A2007086
Award Type:
Standard
Award Region:
US Northwestern

PGlycoprotein and Alzheimer's Disease

Details

P-glycoprotein (P-gp) is an export pump that is highly active at the barrier that separates brain tissue from blood (called the blood brain barrier or BBB). P-gp can transport amyloid-β (Aβ), a compound that accumulates in the brain of people with Alzheimer's disease (AD). We believe that reduced activity of P-gp at the BBB results in accumulation of Aβ in the brain of patients with AD. In the proposed study we will compare P-gp activity at the BBB in patients with AD and in age-matched volunteers without AD, using a method called positron emission tomography (PET). The proposed studies are particularly relevant to Alzheimer's disease for a number of reasons. For the first time, our studies will test the idea that P-gp activity at the BBB is compromised in AD. If it is, we will test in future studies if compounds that are known to increase P-gp activity in the human intestine, such as rifampin or St. John's Wort, can increase P-gp activity at the BBB. If both or one of these compounds do increase P-gp activity at the BBB, they can be tested for their effectiveness in stopping progression of Alzheimer's disease.
Don't miss out.
Receive research updates, inspiring stories, and expert advice
Please enter your first name.
Please enter your last name.
Keep me informed about: *
Please select at least one.
You must select at least one disease category.